CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV - CLINUVEL PHARMACEUTICALS LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$15.15

16 Apr
2024

-0.050

OPEN

$15.08

-0.33%

HIGH

$15.17

74,156

LOW

$14.95

TARGET
$18.75 23.8% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 69.5 xxx
DPS (cps) xxx N/A 6.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 21.8 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx N/A 9.1% xxx

Dividend yield today if purchased 3 years ago: 0.17%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.33

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx61.9
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx78.3 M
Book Value Per Share xxxxxxxxxxxxxxx333.2
Net Operating Cash Flow xxxxxxxxxxxxxxx36.9 M
Net Profit Margin xxxxxxxxxxxxxxx39.08 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx21.09 %
Return on Invested Capital xxxxxxxxxxxxxxx20.97 %
Return on Assets xxxxxxxxxxxxxxx18.04 %
Return on Equity xxxxxxxxxxxxxxx21.09 %
Return on Total Capital xxxxxxxxxxxxxxx27.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx33.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx157 M
Price To Book Value xxxxxxxxxxxxxxx5.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

26/02/2024

3

Hold

$18.00

18.81%

Operating expenses in the 1H for Clinuvel Pharmaceuticals materially outpaced revenue, resulting in an underlying earnings (EBIT) decline of -13%, explains Ord Minnett.

Disappointing sales growth of 4% constant currency versus 19% in the previous corresponding period was partly due to timing issues.

Operating expenses grew due to a 10% rise in employees and a new commercial office facility, explains the analyst.

The broker feels demand for Scenesse is slowing more than anticipated though the valuation impact is largely offset by the time value of money, and the $18 target and Accumulate rating are maintained.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 7.00 cents and EPS of 71.20 cents.
Ord Minnett forecasts a full year FY25 dividend of 8.00 cents and EPS of 82.40 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

CUV STOCK CHART